萬達電影(002739.SZ)擬定增募資不超43.5億元 實際募集資金淨額28.96億元
格隆匯 11 月 9日丨萬達電影(002739.SZ)公佈,公司第五屆董事會第十八次會議決議,根據公司非公開發行股票預案,此次發行擬募集資金總額(含發行費用)不超過43.5億元,扣除發行費用後的募集資金淨額將用於新建影院項目和補充公司流動資金及償還借款。鑑於此次非公開發行實際募集資金淨額約28.96億元,根據股東大會授權,董事會同意公司對募集資金投資項目擬投入募集資金金額做出相應調整,不足部分由公司以自有資金或通過其他融資方式解決。此次非公開發行有利於公司進一步優化財務結構,滿足公司日常經營資金需求,為後續業務發展提供有利保障。調整後募投項目投入情況如下:

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.